Rosetta Genomics Ltd. Announces the Appointment of J. Michael French to President of its U.S Subsidiary, Rosetta Genomics, Inc.

REHOVOT, Israel and NEW BRUNSWICK, New Jersey, May 3

May 03, 2007, 01:00 ET from Rosetta Genomics Ltd

/PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd. (NASDQ: ROSG) announced
 today the appointment of J. Michael French as the new President of its U.S.
 subsidiary, Rosetta Genomics, Inc.
     Mr. French brings to Rosetta seventeen years of business and
 operational experience in both the pharmaceutical and biotechnology
 industries most recently as Senior Vice President, Corporate Development at
 Sirna Therapeutics, Inc. At Sirna, Mr. French was responsible for Sirna's
 corporate development activities, including partnerships, collaborations,
 product licensing, and mergers and acquisitions. In his eighteen months at
 Sirna, the company established two major pharmaceutical collaborations and
 was acquired by Merck & Co in December 2006 for $1.1 billion.
     "Rosetta has significant potential and now requires a solid,
 experienced and innovative management team to take us to the next level,"
 stated Amir Avniel, Rosetta CEO. "Michael brings to Rosetta the expertise
 and leadership to build that team and advance our technology in multiple
 areas. We believe his accomplishments in negotiating and closing high value
 strategic alliances as well as his ability to establish strong investor
 relationships will be instrumental to our success. We are very pleased to
 have Michael join us at Rosetta."
     "Rosetta is a cutting-edge biotechnology company with tremendous
 opportunity," said Michael French. "I am extremely excited to be a part of
 the Rosetta team. I look forward to helping the company further establish
 its leadership position in the field of microRNAs and to advancing the
 technology platform across both the diagnostic and therapeutic sectors."
     Prior to joining Sirna, Mr. French was the Chief Business Officer at
 Entelos, Inc where he was responsible for business development, alliance
 management and corporate communication activities helping to expand
 Entelos' business from technology-based research partnerships to
 therapeutic focused co-development collaborations. Earlier in his career,
 he developed global strategic alliances for Farma Biagini S.p.A. and helped
 successfully launch Kogenate(R) (a recombinant Factor VIII product) for
 Bayer AG. Mr. French is a former U.S. Army officer who served as the Senior
 Medical Intelligence Analyst during Operation Desert
     Storm. Among his military decorations are the Bronze Star Medal and
 Defense Meritorious Service Medal. Mr. French holds a B.S. in aerospace
 engineering from the U.S. Military Academy at West Point and a M.S. in
 physiology and biophysics from Georgetown University.
     About Rosetta Genomics
     Rosetta Genomics (Nasdaq:   ROSG) is a leader in the development of
 microRNA-based diagnostics and therapeutics. Founded in 2000, the company's
 integrative research platform combining bioinformatics and state-of-the-art
 laboratory processes has led to the discovery of hundreds of biologically
 validated novel human microRNAs. Building on its strong IP position and
 strategic alliances with leading biotechnology companies, Rosetta Genomics
 is working to develop a full range of diagnostic and therapeutic products
 based on microRNAs. The company's primary focus is in the development of
 microRNA-based products to diagnose and treat different forms of cancer and
 infectious diseases.
     Media & Investors
     Ron Kamienchick
     T: +972-8-948-4785

SOURCE Rosetta Genomics Ltd